Drug Approval | November 09, 2023
Lupin launches Rocuronium Bromide injection in US
Rocuronium Bromide Injection had estimated annual sales of USD 54 million in the US (IQVIA MAT August 2023).
Rocuronium Bromide Injection had estimated annual sales of USD 54 million in the US (IQVIA MAT August 2023).
Animations, colors, and shapes help to improve poor situational awareness, which is responsible for 81.5% of anesthesia-related errors
Ephedrine Sulfate Injection USP, 50 mg/mL had annual sales of USD 52 mn in the United States
Rocuronium Bromide Injection is a neuromuscular blocking agent
Clinical studies are expected to start in Q2 2023.
Themis will market this drug with the brand name REMITHEM.
This is the first injectable product approval from our General Sterile Facility (F-3) which was inspected in August, 2022.
Marinus has broadened inclusion criteria in the RAISE trial to allow for enrollment of patients previously treated with IV anesthesia.
It enables precise visualization and treatment access to the left heart
Yashoda Hospitals Hyderabad has earned the distinction of becoming the first to introduce BTVA in India
Subscribe To Our Newsletter & Stay Updated
